The administration of the anti-IL-22 monoclonal antibody fezakinumab to moderate-to-severe adult AD patients showed clinical and transcriptomic improvements in patients with high IL-22-baseline expression (2). This evidence concerns the gene IL22 and Alzheimer disease.